TG Therapeutics' Briumvi has shown strong revenue growth, with $310 million in FY24, and is expected to reach $540 million in ...

In a report released today, Alec Stranahan from Bank of America Securities maintained a Sell rating on TG Therapeutics (TGTX – Research ...

Learn more about whether Neurocrine Biosciences, Inc. or TG Therapeutics, Inc. is a better investment based on AAII's A+ ...

Shares of TG Therapeutics, Inc. TGTX have rallied 29.5% in the past three months against the industry’s decline of 11.2%. The ...

TG Therapeutics (TGTX) stock spikes as Roche (RHHBY) fails in a Phase 3 trial for a high dose version of its multiple sclerosis therapy Ocrevus. Read more here.

We recently shared a list of 10 Best Short Squeeze Stocks To Buy According to Analysts. In this article, we will see how TG Therapeutics, Inc. (NASDAQ:TGTX) compares to the other top short squeeze ...

TG Therapeutics, Inc. NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of two journal articles one describing the evolution of CD20 ...

This leads investors to also remain optimistic about rising dividends in the future. TG Therapeutics has a better P/E ratio of 244.73 than the aggregate P/E ratio of 41.86 of the Biotechnology ...

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a ...

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI ® (ublituximab-xiiy) in patients with relapsing ...

Shares of TG Therapeutics, Inc. TGTX have rallied 29.5% in the past three months against the industry’s decline of 11.2%. The company’s sole marketed drug Briumvi (ublituximab-xiiy ...